Recombinant Rat Angiotensin-converting enzyme (Ace), partial

What are the key specifications of recombinant rat ACE?

Recombinant rat ACE (partial) is typically available as a His-tagged protein with 1313 amino acids. It catalyzes the conversion of angiotensin I to angiotensin II and plays a critical role in blood pressure regulation. The protein is typically produced in E.coli/Yeast expression systems and purified to >90% purity . Its function involves peptidyl-dipeptidase activity that cleaves dipeptides from the C-terminus of various substrates, primarily within the renin-angiotensin system.

What are the optimal storage conditions for recombinant rat ACE?

For reliable experimental outcomes, recombinant rat ACE should be stored at -20°C for regular use. For extended storage periods, maintaining the protein at -80°C is recommended. The typical storage buffer is PBS pH 7.4 with 50% glycerol to maintain stability and prevent freeze-thaw damage . When receiving shipments, it's advisable to briefly centrifuge the vial if any liquid becomes entrapped in the container's cap during transportation.

What assays can be used to measure recombinant rat ACE activity?

Several methodological approaches can be employed to assess ACE activity:

• Fluorogenic substrate assays: Using quenched fluorescent substrates that release fluorescent products upon cleavage.

• HPLC analysis: Measuring the conversion of angiotensin I to angiotensin II.

• Mass spectrometry: Providing detailed analysis of enzyme kinetics and substrate specificity.

• Radioimmunoassays: Using radiolabeled substrates to track conversion products.

When designing these assays, researchers should consider that full inhibition of both angiotensin I and bradykinin cleavage requires blockade of the two ACE active sites in vitro .

How can I optimize experimental conditions for ACE enzymatic studies?

For optimal enzyme kinetic studies with recombinant rat ACE:

• Buffer composition: ACE activity is chloride-dependent, with optimal activity typically at physiological pH (7.4-8.0).

• Temperature considerations: Standard assays are performed at 37°C, though lower temperatures may be used for extended incubations.

• Zinc requirements: As a metallopeptidase, ACE requires zinc for catalytic activity; avoid chelating agents in experimental buffers.

• Substrate concentration ranges: Use concentrations spanning from below to well above the Km value (typically 0.2× to 5× Km).

• Positive controls: Include known ACE inhibitors to validate assay performance.

What are the considerations for designing in vivo experiments with recombinant ACE?

When designing in vivo experiments:

• Dosing regimens: For comparison, studies with recombinant human ACE2 have used 0.8 mg/kg for acute studies and 2 mg/kg/day for chronic experiments .

• Administration routes: Intravenous administration is common for immediate effects, while osmotic pumps may be preferred for sustained delivery.

• Sample collection timing: Consider pharmacokinetics when scheduling measurements of physiological parameters and biomarkers.

• Control groups: Include appropriate vehicle controls and positive controls (e.g., known ACE inhibitors).

• Physiological readouts: Blood pressure, cardiac parameters, and tissue oxidative stress markers provide comprehensive assessment.

How can recombinant ACE be used to study the differential roles of the two active sites?

Somatic ACE contains two homologous domains, each with a functional active site. Research has revealed fascinating differences between in vitro and in vivo behaviors:

• In vitro studies have demonstrated that complete inhibition of both angiotensin I and bradykinin cleavage requires blockade of both ACE active sites.

• In contrast, in vivo experiments show that selective inhibition of either domain prevents angiotensin I conversion to angiotensin II, while bradykinin protection requires inhibition of both active sites .

This suggests that the in vivo conversion of angiotensin I involves both active sites of ACE that are free of inhibitor, making recombinant ACE valuable for investigating these domain-specific functions using selective inhibitors and mutagenesis approaches.

How can recombinant ACE be used to study oxidative stress mechanisms?

Recombinant ACE provides valuable insights into oxidative stress mechanisms:

• In Wistar-Kyoto rats, angiotensin II infusion (0.1 μg min⁻¹ kg⁻¹) induces a pressor response and activates NADPH oxidase, generating superoxide in the heart, kidney, and blood vessels.

• These effects can be significantly blunted by recombinant human ACE2 administration (2 mg/kg), demonstrating the opposing actions of ACE and ACE2 .

• Treatment with recombinant ACE2 inhibits angiotensin II-mediated phosphorylation of the myocardial extracellular signal-regulated kinase 1/2 pathway, a key signaling mechanism in oxidative stress .

This experimental approach allows researchers to investigate the molecular mechanisms linking the renin-angiotensin system to oxidative stress in various tissues.

What are the implications of ACE/ACE2 balance for cardiovascular research models?

The balance between ACE and ACE2 activities has profound implications for cardiovascular research:

• In spontaneously hypertensive rat (SHR) models, recombinant human ACE2 (2 mg/kg/day) delivered over 14 days partially corrected hypertension and attenuated NADPH oxidase activation and superoxide generation in the heart, kidney, and blood vessels .

• This intervention also affected the plasma levels of angiotensin II (lowering) and angiotensin-(1-7) (elevating), demonstrating the systemic impact of modulating this enzymatic balance .

• These findings suggest that recombinant ACE/ACE2 can be powerful tools for investigating therapeutic approaches to conditions characterized by renin-angiotensin system dysregulation.

How do endogenous inhibitors affect ACE2 activity in experimental systems?

Research has revealed that ACE2 circulates in human plasma, but its activity is suppressed by an endogenous inhibitor . This has important methodological implications:

• Characterization studies indicate this inhibitor is small, hydrophilic, and cationic, but not a divalent metal cation .

• The inhibitor remains soluble in acetonitrile (ACN) at concentrations up to 40% and is relatively resistant to heating (80°C for 20 min) .

• The inhibition appears specific for ACE2, as neprilysin and thimet oligopeptidase were unaffected by the inhibitor fraction .

• To accurately measure plasma ACE2 levels, researchers have developed anion exchange methods that remove this inhibitor, allowing detection using sensitive quenched fluorescent substrate-based assays .

Understanding these endogenous inhibitory mechanisms is crucial for designing accurate ACE2 activity assays and interpreting experimental results.

How does research with recombinant rat ACE translate to human cardiovascular pathophysiology?

Research using recombinant rat ACE offers several translational insights:

• The gene duplication of ACE in vertebrates may represent an evolutionary mechanism for differentially regulating the cleavage of angiotensin I and bradykinin, which has significant implications for understanding human cardiovascular regulation .

• Studies in rat models have demonstrated that recombinant ACE2 can attenuate oxidative stress, NADPH oxidase activity, and ERK1/2 signaling, suggesting potential therapeutic applications for human cardiovascular diseases .

• The differential mechanisms by which the two active sites of ACE contribute to angiotensin I conversion versus bradykinin inactivation in vivo may inform more targeted pharmacological approaches in humans .

These findings highlight the value of rat models for understanding the complex interplay between the renin-angiotensin and kallikrein-kinin systems in human pathophysiology.

What insights has recombinant ACE2 research provided for acute respiratory conditions?

Recombinant human ACE2 has been investigated for potential therapeutic applications in respiratory conditions:

• GSK2586881, a recombinant form of human ACE2, was studied for its effect on hypoxic pulmonary vasoconstriction (HPV) in healthy adult volunteers during exercise under hypoxic conditions .

• While well-tolerated, GSK2586881 (0.8 mg/kg) did not impact the acute HPV response, suggesting that HPV occurs independently of renin-angiotensin system peptides under the experimental conditions tested .

• These findings contribute to understanding the role of ACE2 in pulmonary physiology and indicate that the hypoxic pulmonary vascular response may involve mechanisms distinct from the systemic renin-angiotensin system .

• More recently, recombinant human ACE2 has been investigated as a potential therapeutic for SARS-CoV-2 infection, where it may inhibit binding of the virus spike protein .

This research demonstrates how investigations with recombinant ACE/ACE2 can provide unexpected insights into physiological mechanisms and potential therapeutic approaches.

What are common challenges in expressing and purifying recombinant rat ACE?

Researchers should be aware of several technical challenges:

• Protein size: At 1313 amino acids , rat ACE is a large protein that can be difficult to express at high yields in heterologous systems.

• Expression systems: While E.coli and yeast systems are commonly used , mammalian expression systems may be necessary for proper post-translational modifications.

• Solubility issues: The membrane-bound nature of native ACE can lead to solubility problems with recombinant versions.

• Maintaining enzymatic activity: Preserving the zinc-dependent catalytic activity during purification requires careful buffer optimization.

• Handling: Small volumes of recombinant ACE may occasionally become entrapped in the vial seal during shipment and storage, requiring brief centrifugation .

How can researchers distinguish between ACE and ACE2 activities in experimental samples?

Differentiating ACE and ACE2 activities requires careful methodological approaches:

• Substrate selection: ACE converts angiotensin I to angiotensin II and inactivates bradykinin, while ACE2 converts angiotensin II to angiotensin-(1-7) .

• Specific inhibitors: ACE inhibitors (e.g., captopril, lisinopril) do not inhibit ACE2, allowing selective measurement of ACE2 activity.

• pH optimization: ACE and ACE2 have different pH optima for catalytic activity.

• Removal of endogenous inhibitors: For plasma samples, anion exchange methods can remove the endogenous ACE2 inhibitor to allow accurate measurement of ACE2 activity .

• Immunodepletion: ACE2 can be immunodepleted from samples using specific antibodies to confirm the specificity of measured activities .

What analytical methods provide the most reliable quantification of ACE activity?

For reliable quantification of ACE activity:

• Quenched fluorescent substrate (QFS) assays offer high sensitivity and specificity, with inter- and intra-assay coefficients of variance reported at 13.7% and 7.1%, respectively, for ACE2 .

• Recovery validation: Methods should be validated by measuring recovery of spiked recombinant enzyme. For ACE2, recovery rates >90% have been reported using anion exchange methods .

• Standard curves: Creating standard curves with known concentrations of purified recombinant enzyme allows semi-quantification of endogenous enzyme in biological samples .

• Multiple substrates: Using multiple substrates can provide more comprehensive assessment of enzymatic activity profiles.

• Mass spectrometry: For definitive product identification, mass spectrometry offers unparalleled specificity in identifying cleavage products.

How might recombinant ACE/ACE2 contribute to understanding emerging cardiovascular diseases?

Recombinant ACE and ACE2 offer promising avenues for investigating:

• The role of RAS dysregulation in pathologies beyond traditional hypertension, such as pulmonary arterial hypertension, heart failure with preserved ejection fraction, and diabetic cardiomyopathy.

• Tissue-specific RAS regulation using targeted delivery of recombinant enzymes to specific organs or tissues.

• Sex differences in RAS function and response to modulation, which may explain differential cardiovascular disease risk between males and females.

• Age-related changes in the balance between classical (ACE/Ang II) and counter-regulatory (ACE2/Ang-(1-7)) axes of the RAS.

• Interactions between the RAS and other regulatory systems, such as the endothelin, natriuretic peptide, and sympathetic nervous systems.

What are emerging technologies for studying ACE/ACE2 dynamics?

Cutting-edge approaches for ACE/ACE2 research include:

• CRISPR-Cas9 gene editing to create precise modifications in ACE/ACE2 genes or regulatory elements.

• Single-cell RNA sequencing to reveal cell-specific expression patterns and responses to RAS modulation.

• Advanced imaging techniques for real-time visualization of enzyme activity in living systems.

• Computational modeling of enzyme-substrate interactions to guide the development of more selective modulators.

• Organ-on-chip technologies that can recapitulate the complex tissue environments where ACE/ACE2 function.

These technologies promise to provide unprecedented insights into the complex roles of ACE and ACE2 in health and disease, facilitating the development of more targeted therapeutic approaches.